摘要
目的探讨拉贝洛尔、硫酸镁联合地屈孕酮治疗早发型重症子痫前期的临床效果及安全性。方法将98例早发型重症子痫前期孕妇随机分为治疗组和对照组,每组各49例。对照组患者采用拉贝洛尔联合硫酸镁治疗,治疗组患者在对照组基础上采用地屈孕酮治疗,比较两组患者治疗前与治疗1周后收缩压(SBP)、舒张压(DBP)、疗效、不良反应发生情况及最后的分娩方式、妊娠结局。结果治疗前两组患者SBP、DBP组间比较差异均无显著性(P>0.05);治疗后两组患者SBP、DBP均较治疗前明显好转,且治疗组优于对照组,差异均具有显著性(P<0.05);治疗组显效27例(55.1%),有效20例(4.82%),无效2例(4.08%),总有效率为95.92%;对照组显效19例(38.78%),有效21例(42.86%),无效8例(18.37%),总有效率为81.63%,两组患者总有效率比较差异具有显著性(P<0.05);治疗组患者不良反应发生率(12.24%)明显低于对照组(28.57%),差异具有显著性(P<0.05);治疗组患者顺产36例(73.47%),剖宫产10例(20.41%),对照组分别为22例(44.90%)、19例(38.78%),两组比较差异具有显著性;两组患者妊娠结局比较差异均无显著性(P>0.05)。结论拉贝洛尔、硫酸镁联合地屈孕酮治疗早发型重症子痫前期效果明显优于拉贝洛尔联合硫酸镁,且不良反应发生率更低,值得临床推广应用。
Objective To explore the clinical effect and safety of rabe noel, magnesium sulfate dydrogesterone treatment on early-onset severe preeclampsia. Method 98 cases of early onset severe preeclampsia in pregnant women were randomly divided into treatment group and control group, 49 cases in each group. Control group were treated by rabe noel joint magnesium sulfate treatment, treatment group patients on the basis of control group with flexor progesterone therapy, compared two groups of patients before and after 1 week treatment systolic blood pressure（SBP）, diastolic blood pressure（DBP）, curative effect, adverse reaction and the final way of delivery and pregnancy outcome. Result Before treatment the SBP, DBP between two groups had no significant differences（P〈0.05）; two groups after treatment with SBP, DBP had significant difference compared with before treatment（P〈0.05）, blood pressure in both groups after treatment significantly improved than before treatment, and treatment group was better than that of control group, the comparison between groups had significant difference（P〈0.05）; treatment group 27 cases（55.1%） were markedly improved, 20 cases（4.82%） were effective, 2 cases（4.08%） were invalid, the total effective rate was 95.92%; control group 19 cases were markedly improved（38.78%）, 21 cases（42.86%） were effective, 8 cases（18.37%） were invalid, the total effective rate was 81.63%, total effective rate in both groups had significant difference（P0.05）; incidence of adverse reactions in treatment group（12.24%） was obviously lower than control group（28.57%）, with significant difference（P〈0.05）; natural labor 36 cases（73.47%） in treatment group, 10 cases（20.41%） of cesarean section, control group were 22 cases（44.90%）, 19 cases（38.78%）, two groups had significant difference（P〉0.05）; two groups of patients pregnancy outcomes showed no significant difference（P〉0.05）. Conclusion Rabe noel, magnesium sulfate dydrogesterone treatment of early-onset severe preeclampsia is better than noel combined with magnesium sulfate rabe, has a lower incidence of adverse reactions, worthy of clinical application.
出处
《中国医学前沿杂志（电子版）》
2014年第11期71-73,共3页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
关键词
拉贝洛尔
硫酸镁
地屈孕酮
重症子痫
Rabe noel
Magnesium sulfate
Flexor progesterone
Severe preeclampsia
